Athenex

9

Active INDs

4

Technology Platforms

600

Employees

Recent News

2019-12-11T07:00:00

Athenex Announces Details of Investor Event and Webcast at SABCS on December 13, 2019

2019-12-05T08:00:00

Athenex Announces $60 Million Private Placement

2019-11-19T09:05:00

Athenex Announces Key Company Activities at San Antonio Breast Cancer Symposium

2019-11-07T07:00:00

Athenex, Inc. Announces Third Quarter 2019 Financial Results

2019-10-30T07:00:00

Athenex Announces European Commission Grants Orphan Designations for Paclitaxel and Encequidar for the Treatment of Soft Tissue Sarcoma

2019-10-28T03:30:00

Athenex Announces Progress Update from Partner Almirall on Tirbanibulin Ointment

2019-10-24T07:00:00

Athenex Provides An Update to Shareholders

2019-10-24T07:00:00

Athenex Provides An Update to Shareholders

2019-09-23T07:00:00

Athenex to Highlight Oral Paclitaxel Clinical Programs Targeting Various Solid Tumors at the ESMO Congress 2019

Other Highlights

Photography by Christopher Galluzzo / Nasdaq, Inc.

Photography by Christopher Galluzzo / Nasdaq, Inc.

On June 14, 2017, Athenex celebrated its initial public offering (IPO) at the Nasdaq MarketSite in Times Square.

Athenex is building a 409,000 square foot manufacturing facility in Dunkirk, NY, with support from New York State.